HYI

Across TCGA pan-cancer cohorts, HYI mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated HYI data layer compared with 24 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher HYI mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated HYI expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

PDAC, CCRCC, and LUAD are the cancer types where HYI mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	All	0.588	0.272	<.001	79	view →
CCRCC	DFS	Median	III,IV	0.860	0.523	.007	33	view →
LUAD	OS	Median	II,III,IV	0.795	1.000	.005	20	view →
COAD	DFS	Median	All	0.904	1.000	.034	12	view →
UCEC	DFS	Quartile	III,IV	0.247	1.000	.027	8	view →
GBM	DFS	Quartile	All	0.939	0.701	.003	5	view →
HNSC	OS	Median	II,III,IV	0.953	1.000	.019	4	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

HYI–PDAC (DFS)

Open the PDAC breakdown →